Matthew M. Riggs, Ph.D.

Chief Science Officer

Matt offers over 16 years of industry experience including the application of modeling and simulation for clinical pharmacology and later phase drug development decisions. Matt’s interests include the development and application of mechanistic exposure-response and systems pharmacology models to quantitatively integrate physiology, pharmacology, senescence and disease understandings; this to guide translational and clinical research toward improved preventative and interventional therapeutics.

Recent publications by this scientist

Quantification of the Impact of Partition Coefficient Prediction Methods on PBPK Model Output Using a Standardized Tissue Composition

July 22, 2020

Utsey, Kiersten, Madeleine S. Gastonguay, Sean Russell, Reed Freling, Matthew M. Riggs, and Ahmed Elmokadem. 2020. Drug Metabolism and Disposition: The Biological Fate of Chemicals, July. https://doi.org/10.1124/dmd.120.090498.

View More

Low-Dose Empagliflozin as Adjunct-to-Insulin Therapy in Type 1 Diabetes: A Valid Modeling and Simulation Analysis to Confirm Efficacy

December 19, 2019

Perkins BA, Soleymanlou N, Rosenstock J, Skyler JS, Laffel LM, Liesenfeld KH, Neubacher D, Riggs MM, Johnston CK, Eudy-Byrne RJ, Elmokadem A, George JT, Marquard J, Nock V.  Diabetes, Obesity & Metabolism, 2019 Dec 19. Available from: https://doi.org/10.1111/dom.13945.

View More

Toward Progress in Quantitative Translational Medicine: A Call to Action

November 25, 2019

Venkatakrishnan, Karthik, Songmao Zheng, Cynthia J. Musante, Jin Y. Jin, Matthew M. Riggs, Sriram Krishnaswami, and Sandra A. G. Visser. 2020. “Toward Progress in Quantitative Translational Medicine: A Call to Action.” Clinical Pharmacology and Therapeutics 107 (1): 85–88.  Available from: https://doi.org/10.1002/cpt.1687

View More